53 related articles for article (PubMed ID: 17127229)
1. Expression of genes related to activity of oxaliplatin and 5-fluorouracil in endoscopic biopsies of primary esophageal cancer in patients receiving oxaliplatin, 5-flourouracil and radiation: characterization and exploratory analysis with survival.
Leichman L; Lawrence D; Leichman CG; Nava H; Nava E; Proulx G; Clark K; Khushalani NI; Berdzik J; Greco W; Smith P; Creaven PJ; Kepner JL; Javle MM; Pendyala L
J Chemother; 2006 Oct; 18(5):514-24. PubMed ID: 17127229
[TBL] [Abstract][Full Text] [Related]
2. Polyamine catabolism in colorectal cancer cells following treatment with oxaliplatin, 5-fluorouracil and N1, N11 diethylnorspermine.
Hector S; Tummala R; Kisiel ND; Diegelman P; Vujcic S; Clark K; Fakih M; Kramer DL; Porter CW; Pendyala L
Cancer Chemother Pharmacol; 2008 Aug; 62(3):517-27. PubMed ID: 17987291
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of oxaliplatin in combination with cisplatin, protacted-infusion fluorouracil, and radiotherapy in advanced esophageal and gastroesophageal carcinoma.
Maurel J; Cervantes A; Conill C; Salazar R; Martin-Richard M; Pera M; Manzano H; Chirivella I; Gallego R; Marfa X
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):91-6. PubMed ID: 15850907
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer.
Warnecke-Eberz U; Hokita S; Xi H; Higashi H; Baldus SE; Metzger R; Brabender J; Bollschweiler E; Mueller RP; Dienes HP; Hoelscher AH; Schneider PM
Oncol Rep; 2005 Jun; 13(6):1241-6. PubMed ID: 15870949
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of expression of ERCC 1 and GST-p for 5-fluorouracil/oxaliplatin chemotherapy in advanced colorectal cancer.
Noda E; Maeda K; Inoue T; Fukunaga S; Nagahara H; Shibutani M; Amano R; Nakata B; Tanaka H; Muguruma K; Yamada N; Yashiro M; Ohira M; Ishikawa T; Hirakawa K
Hepatogastroenterology; 2012; 59(113):130-3. PubMed ID: 21940361
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
[TBL] [Abstract][Full Text] [Related]
9. [Nedaplatin and 5-fluorouracil combined with radiotherapy for advanced esophageal cancer].
Nakamura T; Ide H; Eguchi R; Hayashi K; Ota M; Narumiya K; Takasaki K; Mitsuhashi M
Gan To Kagaku Ryoho; 2003 Jun; 30(6):803-7. PubMed ID: 12852347
[TBL] [Abstract][Full Text] [Related]
10. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.
Rödel C; Liersch T; Becker H; Fietkau R; Hohenberger W; Hothorn T; Graeven U; Arnold D; Lang-Welzenbach M; Raab HR; Sülberg H; Wittekind C; Potapov S; Staib L; Hess C; Weigang-Köhler K; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R;
Lancet Oncol; 2012 Jul; 13(7):679-87. PubMed ID: 22627104
[TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
Chau I; Webb A; Cunningham D; Hill M; Waters JS; Norman A; Massey A
Br J Cancer; 2001 Nov; 85(9):1258-64. PubMed ID: 11720458
[TBL] [Abstract][Full Text] [Related]
12. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer.
Joshi MB; Shirota Y; Danenberg KD; Conlon DH; Salonga DS; Herndon JE; Danenberg PV; Harpole DH
Clin Cancer Res; 2005 Mar; 11(6):2215-21. PubMed ID: 15788669
[TBL] [Abstract][Full Text] [Related]
13. Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response.
Javle M; Pande A; Iyer R; Yang G; LeVea C; Wilding G; Black J; Nava H; Nwogu C
Am J Clin Oncol; 2008 Aug; 31(4):329-34. PubMed ID: 18845990
[TBL] [Abstract][Full Text] [Related]
14. Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine.
Monzo M; Moreno I; Navarro A; Ibeas R; Artells R; Gel B; Martinez F; Moreno J; Hernandez R; Navarro-Vigo M
Oncology; 2007; 72(5-6):364-70. PubMed ID: 18204222
[TBL] [Abstract][Full Text] [Related]
15. Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel.
Homann N; Pauligk C; Luley K; Werner Kraus T; Bruch HP; Atmaca A; Noack F; Altmannsberger HM; Jäger E; Al-Batran SE
Int J Cancer; 2012 Apr; 130(7):1706-13. PubMed ID: 21618509
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of oxaliplatin in combination with leucovorin and fluorouracil as first-line chemotherapy in patients with metastatic squamous cell carcinoma of esophagus.
Wang J; Chang J; Yu H; Wu X; Wang H; Li W; Ji D; Peng W
Cancer Chemother Pharmacol; 2013 Apr; 71(4):905-11. PubMed ID: 23370661
[TBL] [Abstract][Full Text] [Related]
17. Correlating dose and volume of irradiated lung with pulmonary function tests.
Phillips TL
Cancer J; 2002; 8(6):438-9. PubMed ID: 12500851
[No Abstract] [Full Text] [Related]
18. Chemoradiation is a tolerable therapy for older adults with esophageal cancer.
Nallapareddy S; Wilding GE; Yang G; Iyer R; Javle M
Anticancer Res; 2005; 25(4):3055-60. PubMed ID: 16080565
[TBL] [Abstract][Full Text] [Related]
19. [Pathologic complete response of thoracic esophageal cancer developing after gastrectomy to neoadjuvant low-dose nedaplatin (CDGP), 5-fluorouracil and radiotherapy].
Takemura M; Osugi H; Lee S; Nishikawa T; Fukuhara K; Iwasaki H
Gan To Kagaku Ryoho; 2005 Jul; 32(7):1023-7. PubMed ID: 16044966
[TBL] [Abstract][Full Text] [Related]
20. Predictors of response to chemo-radiotherapy and radiotherapy for esophageal squamous cell carcinoma.
Miyazaki T; Kato H; Faried A; Sohda M; Nakajima M; Fukai Y; Masuda N; Manda R; Fukuchi M; Ojima H; Tsukada K; Kuwano H
Anticancer Res; 2005; 25(4):2749-55. PubMed ID: 16080521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
